A Phase 3 interventional study of remestemcel-L in Grade B aGVHD, Grade C aGVHD and Grade D aGVHD, sponsored by Mesoblast, Inc.. Completed at 20 sites in United States. Open to participants aged 2 Months to 17 Years. Per ClinicalTrials.gov, last updated 2022-03-17.
Sponsored by Mesoblast, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study plans to treat at least 60 pediatric participants, male and female, between the ages of 2 months and 17 years inclusive with aGVHD following allogeneic hematopoietic stem cell transplant (HSCT) that has failed to respond to treatment with systemic corticosteroid therapy. Participants may have Grades C and D aGVHD involving the skin, liver and/or gastrointestinal (GI) tract or Grade B aGVHD involving the liver and/or GI tract, with or without concomitant skin disease.
Remestemcel-L will be evaluated in pediatric participants with aGVHD following allogeneic HSCT that has failed to respond to treatment with systemic corticosteroid therapy.
Mesoblast, Inc. is the lead sponsor of 19 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 4 (25%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants who have had persistent GI GVHD manifested by diarrhea with stool volume \< 500 mL/kg/day (for participants >50 kg) or \<30 mL/kg/day (for participants ≤50 kg). See GVHD Organ Severity Criteria (Table 2) for values in mL/m\^2. In the absence of nausea or vomiting, participants could have been considered to have Grade B GVHD if:
Participant must have adequate renal function as defined by a calculated of >30 mL/min per 1.73 m\^2. For participants 1 to 18 years of age, creatinine clearance is calculated using the Bedside Schwartz equation:
(GFR, in mL/min per 1.73 m\^2) = (0.413 * height [cm])/serum creatinine (mg/dL)
For participants younger than 1 year of age, renal function is determined using the Schwartz equation adjusted for this age group:
Creatinine clearance (mL/min per 1.73 m\^2= (height [cm] x 0.45)/ (serum creatinine [mg/dL]).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were treated with intravenous (IV) remestemcel-L at a dose of 2×10\^6 mesenchymal stromal cells (MSCs)/kilogram (kg) actual body weight at Screening, twice per week, for each of 4 consecutive weeks (initial therapy) given at least 3 days apart and no more than 5 days apart for any infusion. Eligible participants received an additional once per week infusion, for each of 4 consecutive weeks (continued therapy) of remestemcel-L and twice per week infusions, for each of 4 consecutive weeks (aGVHD flare therapy) of remestemcel-L at the same initial therapy dose of 2×10\^6 MSCs/kg actual body weight at Screening.
Drug: remestemcel-L
Participants were treated with IV remestemcel-L at a dose of 2 x 10\^6 MSC/kg (actual body weight at screening) twice per week for each of 4 consecutive weeks. Infusions were administered at least 3 days apart and no more than 5 days apart for any infusion.
Overall Response Rate (ORR) at Day 28 Post Initiation of Therapy
ORR was defined as the percentage of participants who had achieved overall response. Overall response was defined as complete response (CR) plus partial response (PR) as per aGVHD response criteria. CR was defined as resolution of aGVHD in all involved organs. PR was defined as organ improvement of at least 1 stage without worsening of any other organ.
Time frame: Day 28
Overall Survival (OS) Rate at Day 100 Post Initiation of Therapy
Overall survival rate was defined as percentage of participants who survived. OS was defined as the time to death from the start of drug therapy.
Time frame: Day 100
OS Rate at Day 100 Post Initiation of Therapy, Stratified by Responder Status at Day 28
Overall survival rate was defined as percentage of participants who survived. OS was defined as the time to death from the start of drug therapy.
Time frame: Day 100
OS Rate at Day 100 Post Initiation of Therapy, Stratified by Baseline aGVHD Grade
OS rate was defined as percentage of participants who survived. OS was defined as the time to death from the start of drug therapy. Maximum severity of acute GVHD was assessed by using International Bone Marrow Transplant Registry (IBMTR) index. The severity index was defined as: Grade A (skin Stage 1: extent of rash \<25%); Grade B (skin Stage 2: extent of rash 25 to 50% or liver Stage 1 to 2: total bilirubin 34 to 102 micromoles per liter \[mcmol/L\] or intestinal tract Stage 1 to 2: volume of diarrhea 550 to 1500 milliliters per day \[mL/day\]); Grade C (skin Stage 3: extent of rash \> 50% or liver Stage 3: total bilirubin 103 to 255 mcmol/L or intestinal tract Stage 3: volume of diarrhea \>1500 mL/day); Grade D (skin Stage 4: extent of rash bullae or liver Stage 4: total bilirubin \>255 or intestinal tract Stage 4: volume of diarrhea severe pain and ileus).
Time frame: Day 100
OS Rate at Day 100 Post Initiation of Therapy, Stratified by Organ Involvement
OS rate was defined as percentage of participants who survived. OS was defined as the time to death from the start of drug therapy. The data was summarized for organ involvement: skin only, lower GI only, and multi-organ.
Time frame: Day 100
OR Rate at Day 56 and 100 Post Initiation of Therapy
OR rate was defined as the percentage of participants who had achieved overall response. Overall response was defined as CR plus PR as per aGVHD response criteria. CR was defined as resolution of aGVHD in all involved organs. PR was defined as organ improvement of at least 1 stage without worsening of any other organ.
Time frame: Day 56 and Day 100
| Milestone | Remestemcel-L 2×10^6 MSCs/kg |
|---|---|
| Started | 55 |
| Full analysis set (fas) | 55 |
| Safety analysis population | 54 |
| Completed | 42 |
| Not completed | 13 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal of consent | 1 |
| Withdrew: Death | 9 |
| Withdrew: Dose not received due to shipping delay | 1 |
| Withdrew: Discontinuation of msc infusion | 1 |
ORR was defined as the percentage of participants who had achieved overall response. Overall response was defined as complete response (CR) plus partial response (PR) as per aGVHD response criteria. CR was defined as resolution of aGVHD in all involved organs. PR was defined as organ improvement of at least 1 stage without worsening of any other organ.
| percentage of participants | Remestemcel-L 2×10^6 MSCs/kg |
|---|---|
| Overall Response Rate (ORR) at Day 28 Post Initiation of Therapy | 69.1 |
Overall survival rate was defined as percentage of participants who survived. OS was defined as the time to death from the start of drug therapy.
| percentage of participants | Remestemcel-L 2×10^6 MSCs/kg |
|---|---|
| Overall Survival (OS) Rate at Day 100 Post Initiation of Therapy | 74.5 |
Overall survival rate was defined as percentage of participants who survived. OS was defined as the time to death from the start of drug therapy.
| percentage of participants | Remestemcel-L 2×10^6 MSCs/kg |
|---|---|
| Responders | 86.8 |
| Non- Responders | 47.1 |
OS rate was defined as percentage of participants who survived. OS was defined as the time to death from the start of drug therapy. Maximum severity of acute GVHD was assessed by using International Bone Marrow Transplant Registry (IBMTR) index. The severity index was defined as: Grade A (skin Stage 1: extent of rash \<25%); Grade B (skin Stage 2: extent of rash 25 to 50% or liver Stage 1 to 2: total bilirubin 34 to 102 micromoles per liter \[mcmol/L\] or intestinal tract Stage 1 to 2: volume of diarrhea 550 to 1500 milliliters per day \[mL/day\]); Grade C (skin Stage 3: extent of rash \> 50% or liver Stage 3: total bilirubin 103 to 255 mcmol/L or intestinal tract Stage 3: volume of diarrhea \>1500 mL/day); Grade D (skin Stage 4: extent of rash bullae or liver Stage 4: total bilirubin \>255 or intestinal tract Stage 4: volume of diarrhea severe pain and ileus).
| percentage of participants | Remestemcel-L 2×10^6 MSCs/kg |
|---|---|
| Grade B | 50.0 (11.81 to 88.19) |
| Grade C | 82.6 (61.22 to 95.05) |
| Grade D | 73.1 (52.21 to 88.43) |
OS rate was defined as percentage of participants who survived. OS was defined as the time to death from the start of drug therapy. The data was summarized for organ involvement: skin only, lower GI only, and multi-organ.
| percentage of participants | Remestemcel-L 2×10^6 MSCs/kg |
|---|---|
| Skin Only | 78.6 |
| Lower GI Only | 76.2 |
| Multi-organ (Any Combination) | 70.0 |
OR rate was defined as the percentage of participants who had achieved overall response. Overall response was defined as CR plus PR as per aGVHD response criteria. CR was defined as resolution of aGVHD in all involved organs. PR was defined as organ improvement of at least 1 stage without worsening of any other organ.
| percentage of participants | Remestemcel-L 2×10^6 MSCs/kg |
|---|---|
| Day 56 | 58.2 |
| Day 100 | 69.1 |
Collected over From Baseline through 100 days of follow up. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Remestemcel-L 2×10^6 MSCs/kg | 13/55 (23.6%) | 35/54 (64.8%) | 52/54 (96.3%) |
| Event | Remestemcel-L 2×10^6 MSCs/kg |
|---|---|
| PyrexiaGeneral disorders | 5/54 |
| Multiple organ dysfunction syndromeGeneral disorders | 5/54 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 5/54 |
| Pneumatosis intestinalisGastrointestinal disorders | 4/54 |
| Acute graft versus host diseaseImmune system disorders | 3/54 |
| Staphylococcal infectionInfections and infestations | 3/54 |
| Haemolytic uraemic syndromeBlood and lymphatic system disorders | 2/54 |
| Graft versus host disease in skinImmune system disorders | 2/54 |
| BK virus infectionInfections and infestations | 2/54 |
| Escherichia urinary tract infectionInfections and infestations | 2/54 |
| Event | Remestemcel-L 2×10^6 MSCs/kg |
|---|---|
| PyrexiaGeneral disorders | 13/54 |
| Abdominal painGastrointestinal disorders | 10/54 |
| Adenovirus infectionInfections and infestations | 10/54 |
| HypertensionVascular disorders | 10/54 |
| VomitingGastrointestinal disorders | 9/54 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/54 |
| HypotensionVascular disorders | 8/54 |
| Oedema peripheralGeneral disorders | 7/54 |
| Epstein-Barr viraemiaInfections and infestations | 7/54 |
| HyperglycaemiaMetabolism and nutrition disorders | 7/54 |
Full analysis set (FAS) included all participants who provided informed consent, were screened, and were found eligible to enter the study.
| Age, Continuous(years) | Remestemcel-L 2×10^6 MSCs/kg |
|---|---|
| Mean | 7.3 ± 5.45 |
| Sex: Female, Male(Participants) | Remestemcel-L 2×10^6 MSCs/kg |
|---|---|
| Female | 20 |
| Male | 35 |
| Ethnicity (NIH/OMB)(Participants) | Remestemcel-L 2×10^6 MSCs/kg |
|---|---|
| Hispanic or Latino | 18 |
| Not Hispanic or Latino | 36 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Remestemcel-L 2×10^6 MSCs/kg |
|---|---|
| American Indian or Alaska Native | 3 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 8 |
| White | 31 |
| More than one race | 10 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2015 to primary completion in Apr 2018, 34 months.
Results were first posted in Mar 2022, 3 years 11 months after primary completion. A results delay was requested in Feb 2019.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Remestemcel-l